Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by W.H. Cornerstone Investments Inc.

W.H. Cornerstone Investments Inc. increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,099 shares of the medical research company’s stock after acquiring an additional 53 shares during the period. W.H. Cornerstone Investments Inc.’s holdings in Thermo Fisher Scientific were worth $1,114,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Means Investment CO. Inc. increased its stake in Thermo Fisher Scientific by 7.5% in the third quarter. Means Investment CO. Inc. now owns 858 shares of the medical research company’s stock valued at $435,000 after purchasing an additional 60 shares during the last quarter. KMG Fiduciary Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 6.7% during the third quarter. KMG Fiduciary Partners LLC now owns 3,304 shares of the medical research company’s stock worth $1,672,000 after purchasing an additional 207 shares during the last quarter. Penobscot Wealth Management purchased a new stake in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $204,000. Concord Wealth Partners grew its stake in Thermo Fisher Scientific by 10.0% during the 3rd quarter. Concord Wealth Partners now owns 884 shares of the medical research company’s stock worth $447,000 after buying an additional 80 shares during the last quarter. Finally, Everhart Financial Group Inc. lifted its stake in Thermo Fisher Scientific by 5.4% in the third quarter. Everhart Financial Group Inc. now owns 748 shares of the medical research company’s stock valued at $379,000 after buying an additional 38 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last quarter, insiders sold 62,277 shares of company stock worth $35,373,364. 0.34% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Up 0.2 %

TMO stock traded up $1.13 on Friday, hitting $572.38. 1,749,670 shares of the company were exchanged, compared to its average volume of 1,409,187. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The stock has a market capitalization of $218.48 billion, a price-to-earnings ratio of 36.71, a price-to-earnings-growth ratio of 2.37 and a beta of 0.80. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The business’s fifty day moving average is $575.39 and its two-hundred day moving average is $533.63.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research report on Thursday, April 25th. Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Finally, The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.